Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles
نویسندگان
چکیده
منابع مشابه
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet to be licensed. Unlike the strategy to reverse the only oral direct thrombin inhibitor with idaru...
متن کاملOral direct factor Xa inhibitors.
Vitamin K antagonists, such as warfarin, have been the mainstay of oral anticoagulation for many decades. Although effective, warfarin has numerous limitations, including a variable dose requirement from patient to patient because of differences in dietary vitamin K intake, common genetic polymorphisms, and multiple drug interactions that affect its pharmacodynamics and metabolism. Consequently...
متن کاملNovel factor Xa inhibitors: a patent review.
IMPORTANCE OF THE FIELD New oral anticoagulants with favorable safety profiles and fixed doses are required for the management of thromboembolism and stroke prevention in patients with atrial fibrillation. Among them, fXa inhibitors (the so-called xabans) are attractive options that can overcome limitations (e.g., bleeding) of the current oral antithrombotic therapy. The rational design of smal...
متن کاملThe role of factor Xa inhibitors in venous thromboembolism treatment
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer diff...
متن کاملFacts and artefacts of coagulation assays for factor Xa inhibitors.
Direct factor Xa inhibitors are among the compounds at the forefront of clinical development for the prevention and treatment of thromboembolic disorders; of these, rivaroxaban, apixaban and edoxaban (DU-176b) are in the most advanced stages of development. Rivaroxaban is approved in several countries for the prevention of venous thromboembolism (VTE) after elective hip or knee arthroplasty, an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Metabolism and Pharmacokinetics
سال: 2020
ISSN: 1347-4367
DOI: 10.1016/j.dmpk.2019.10.005